No Data
No Data
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn Into More Strength?
Scotiabank Initiates Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $105
UBS Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $188
Express News | Sarepta Therapeutics Shares Are Trading Higher. The Stock Fell on Tuesday After the Company Reported a Patient Death Following Treatment With Elevidys
Sarepta Therapeutics Price Target Maintained With a $163.00/Share by Cantor Fitzgerald
Sarepta Selloff Seen as Buying Opportunity -- Market Talk
Chak : Bastards it should gain 20%
siti_kasim 8⃣4⃣ : hi